ESPE Abstracts

Background: Objective to determine the efficacy of short-term rhGH treatment on metabolic indices in TGHD patients by comparing the changes in blood glucose and lipid levels before and after rhGH replacement therapy.

Methods: The levels of metabolic indices (AST, ALT, TC, TG, HDL-C, LDL-C, FBG, GA, and URIC) in their basic state in TGHD patients were recorded, and differences in these levels between the TGHD and control groups were compared. For the TGHD patients with dyslipidemia, low-dose rhGH replacement therapy was administered for 3 months to evaluate the changes in metabolic indices after treatment. The correlation between IGF-1 SDS and metabolic indices was analyzed.

Results: No difference was observed between the TGHD patients without rhGH treatment and the control group in BMI and SDS, and AST and FBG levels. IGF-1 SDS and HDL-C levels were significantly lower in the TGHD patients without treatment than in the control group (P ≤ 0.001). ALT, TC, TG, LDL-C, GA, and URIC levels were significantly higher in the TGHD patients than in the control group (P < 0.05). IGF-1 SDS levels in the TGHD group treated with rhGH for 3 months were significantly increased (P ≤ 0.001), whereas TC, TG, and URIC levels were significantly decreased (P < 0.05).

Conclusion: The metabolic abnormality in TGHD patients was mainly hyperlipidemia, and low doses of rhGH had a positive effect on decreasing blood lipid levels in the TGHD patients.

Key words: Transition Growth Hormone Deficiency (TGHD); rhGH treatment; Blood lipid; Blood glucose